



 Adaptimmune
Redefining Cancer Treatment

August 2024

Disclaimer

This presentation contains “forward-looking” statements as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission filed for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.



For Us, Fighting Cancer is Personal

Cancer has upended the lives of too many families, fueling our company's drive to fundamentally redefine treatment of some of the most challenging cancer types.

From our commitment to scientific innovation to our perseverance in the development, commercialization and delivery of innovative cell therapies, Adaptimmune is working to radically change and improve the treatment experiences and outcomes for people impacted by cancer.

We know every cancer journey is personal, and for us, it's personal too.

Arming cells. Against cancer. For good.

Adaptimmune: redefining the treatment of solid tumor cancers with cell therapy

***High Value Sarcoma Franchise:
Tecelra and Lete-cel
Transforming the
Sarcoma Space***

 **Tecelra®**
afamitresgene autoleucel
suspension for IV infusion

***Robust Clinical Pipeline:
Progressing
Multiple Large
Opportunity Cell
Therapies***

***Integrated Cell
Therapy Company:
Designed and Built
from the Ground Up***



High value
sarcoma franchise





Tecelra (afami-cel) Receives FDA Accelerated Approval*

***First engineered cell therapy approved*
by FDA for a solid tumor cancer***

. Please see full [Prescribing Information](#), including Boxed Warning and [Medication Guide](#).



*Tecelra approved for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy


🌀 Tecelra approval is first step in building a sarcoma franchise; transforming the treatment paradigm 🌀

Tecelra and lete-cel have the potential to:

- Generate up to \$400M in annual sales at peak
- Operate at ~70% gross margin at peak
- Establish a foundation for a sarcoma franchise

- ~13k diagnosed with soft-tissue sarcoma (STS) in US/year
 - SyS and MRCLS combined = ~10-20% of STS cases
 - ~70% of SyS patients express MAGE-A4³
 - >80% of SyS and MRCLS patients express NY-ESO⁴
 - ~40% of patients will be HLA eligible⁵

Annual Eligible Patients



🌀 Synovial sarcoma and myxoid/round cell liposarcoma (MRCLS): devastating diagnoses, young patients, limited treatments 🌀

- Synovial sarcoma and Myxoid/round cell liposarcoma (MRCLS) are two of more than 50 different types of soft tissue cancers¹
- Soft tissue sarcomas (STSs) are tumors that appear in fat, muscle, nerves, blood vessels, fibrous and deep skin tissues¹
- There are ~ 13,000 new soft tissue cases in the U.S. each year²



Synovial sarcoma



- Often found in the arm, leg, or foot, near joints such as the wrist or ankle as well as lung or abdomen²
- Approximately 5% to 10% of all soft tissue sarcomas²
- Impacts younger people: 1/3 of patients diagnosed under age 30²
- 20% 5-year overall survival³

MRCLS

- Predominantly found in the limbs⁴
- Approximately 5% to 10% of all soft tissue sarcomas⁴
- Impacts middle-aged adults: frequently diagnosed between ages 35-55⁵
- 8% 5-year disease-specific survival⁶

Afami-cel: highly anticipated treatment option for synovial sarcoma

Afami-cel delivers remarkable results ~39% ORR (17/44) and ~12 months DOR in heavily pre-treated patients with advanced disease; median duration of response continues to mature



Brandi Felser, Chief Executive Officer of the Sarcoma Foundation of America:

"I celebrate the promise that breakthrough therapies like afami-cel offer to sarcoma patients. Such advancements offer hope and transformative possibilities for the sarcoma patient community, addressing critical unmet needs and offering increased and improved treatments for people diagnosed with sarcoma. I am hopeful for and excited about a new treatment choice for people diagnosed with synovial sarcoma."

**2022 Vision of
Hope Award
Recipient**




Unprecedented survival reported in patients who respond to afami-cel

Historical outcomes are poor for advanced synovial sarcoma

- Afami-cel responders have a 2-year survival probability of 70%, with median overall survival not yet reached
- Median overall survival of the entire study is ~17 months vs historic control (Pazopinib) of < 12 months¹

2023 ctoS
ANNUAL MEETING




Median Overall Survival 16.9 months (95% CI: 10.9, NE); 45.5% of patients censored at the data cut-off; median follow up time was nearly 33 months.

🌀 Lete-cel: pivotal trial met primary endpoint at interim analysis – next step BLA submission in 2025 🌀

Primary efficacy endpoint met at interim analysis; data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population


40% ORR across both SyS and MRCLS; 10.6 months mDOR as of interim analysis*

- 40% (18/45) of people with synovial sarcoma or MRCLS who have received prior anthracycline treatment had clinical responses with lete-cel
- Primary efficacy endpoint requires 16/60 patients to have a response



2024 ASCO[®]
ANNUAL MEETING


Field team in place, sites engaged, eligibility testing available,
Adaptimmune ready to receive orders



Clear path to access for eligible US synovial sarcoma patients

Favorable payer mix

Synovial Sarcoma Payer Mix



- Commercial
- Medicare Advantage
- Medicare FFS
- Medicaid

Established reimbursement pathway



Positive early engagement



Executing focused launch plans



- ✓ Tecelra granted accelerated approval* on August 1st, 2024
- ✓ Companion CDx approved
- ✓ Commercial, medical affairs and supply teams in place



Commercializing a Sarcoma Franchise

- ✓ Biomarker testing is available nationwide
- ✓ On track to activate 6-10 treatment centers
- ✓ Distribution and cell ordering platform ready to accept orders



Bringing Tecelra to every eligible patient

- ✓ Adaptimmune **Assistup** and operational
- ✓ 60+ sarcoma centers of excellence; 600+ HCPs engaged



Supporting patients and HCPs

Key launch performance indicators:

Patients apheresed # Treatment centers

Initial franchise foundation of up to \$400m US peak year sales, multiple opportunities for expansion

Tecelra and lete-cel
initial approvals in
advanced synovial
sarcoma and MRCLS

Sequential/combination treatment with
Tecelra and lete-cel

Earlier lines of therapy

PRAME (ADP-600) approval

Additional HLA types


Other sarcomas (e.g., osteosarcoma)

Geographic expansion ex-US



Robust pipeline
of cell therapies
for solid tumours

Robust pipeline across broad range of solid tumors

PROGRAM [TARGET]	TRIAL NAME(S) / INDICATION(S) / DESIGN	IND-ENABLING	PHASE 1	PHASE 2/3	REGISTRATION	APPROVAL
afami-cel [MAGE-A4]	SPEARHEAD -1 pivotal trial Synovial Sarcoma					
	SPEARHEAD-3 pediatric basket trial*					
lete-cel [NY-ESO]	IGNYTE-ESO Synovial sarcoma and MRCLS					
uza-cel** [MAGE-A4]	SURPASS-3 registration-directed trial Platinum resistant ovarian cancer; Monotherapy; +/- checkpoint inhibitor					
	SURPASS Ph1 Head & neck cancer Focus on earlier line therapy +/- checkpoint inhibitor					
	SURPASS Ph1 urothelial cancer Focus on earlier line therapy +/- checkpoint inhibitor					
	Ph1 H&N cancer - collaboration 					
ADP-600 [PRAME]	Indications that express PRAME including synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian and head & neck cancers Clinical Indications TBD					
ADP-520 [CD70]	Indications that express CD70 including hematological malignancies: acute myeloid leukemia (AML), lymphoma and renal cell carcinoma (RCC) Clinical Indications TBD					

* Synovial sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma. SPEARHEAD-3 trial enrollment paused as per protocol.


** uzatresgene autoleucel, formerly ADP-A2M4CD8; SURPASS Ph 1 no longer enrolling. Adaptimmune and Galapagos to conduct a clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer

Uza-cel (formerly ADP-A2M4CD8): best indications for product development



35%
Response Rate
In 46 heavily pre-treated
patients across a **broad
range of solid tumors**

50%
Response Rate
in 26 patients with the focus
indications of **ovarian, urothelial,
and head neck cancer**

75%
Response Rate
in 12 patients who received **three or
fewer prior lines of therapy** ("earlier
line") across focus indications



Significant responses with uza-cel monotherapy reported across a broad range of solid tumor types



— CR — PR — SD — PD

- Data from 46 patients (43 evaluable)
- 35% overall response rate
- Approximately 5 months median duration of response

Platinum-resistant ovarian cancer (PROC): area of high unmet medical need

Uza-cel has the opportunity to transform treatment landscape

Ovarian cancer

High Incidence: ~20k/year in US, 55% diagnosed metastatic¹

High Mortality: ~13k US deaths per year¹

- Five-year survival of 51%¹
- 32% survival for those with metastatic disease at diagnosis¹

High rates of resistance to platinum chemo: ~18k US PROC patients in 2023²

Limited number of non-chemo/targeted therapies:

- PARPs: not indicated for PROC
- Elahere: Folate-receptor alpha-positive patients only (35% patient eligibility)³
- Avastin: ~28% of PROC patients respond to therapy⁴



Current treatments may be keeping us alive but at what price and **are limited in how long they work**. Living a full life is often not possible due to the **terrible side effects of treatment**. No one should have to choose between just being alive and actually living (a full life.)

- Stage 4 Ovarian Cancer Survivor


Efficacy supports late-stage trial in ovarian cancer: SURPASS-3

uza-cel - SURPASS PHASE 1 monotherapy arm


- 40% ORR in heavily pretreated people with highly advanced PROC
- 1 confirmed CR and 5 confirmed PRs (6/15)
- Median duration of response 17 weeks (~4 months) – surveillance is ongoing

Phase 2 trial (SURPASS-3) initiated in PROC with monotherapy and in combination with nivolumab

- 66 patient randomized trial
- Combination has potential to increase duration of response
- Opportunity to establish efficacy in a larger set of patients
- SURPASS-3 is potentially registrational



SURPASS-3 trial design



Head & Neck cancer – responses support collaboration with Galapagos and clinical PoC* for decentralized manufacturing platform


Collaboration summary

- Adaptimmune to sponsor Ph1 clinical trial in H&N cancer using Galapagos decentralized manufacturing platform
- Galapagos granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications using Galapagos' innovative decentralized cell therapy manufacturing platform
- Adaptimmune to receive \$70 million upfront payment +\$30 million R&D funding
- Option exercise fees up to \$100 million
- Additional development and sales milestone payments of up to a maximum of \$465 million, plus tiered royalties on net sales



Head & Neck

- Deep anti-tumor responses; 4/5 PRs**



PRAME: Clinically validated “clean” target

Highly expressed across a broad range of solid tumors including ovarian, endometrial, lung, and breast cancers

Near term

- Phase 1 trial
- Dose escalation
- Expansion cohort



Long term

- Next generation enhancements
- Explore synergies with Uza-cel in ovarian cancer



Recent preclinical data presented at ASGCT 2024

- PRAME is an attractive target for adoptive T-cell therapy using affinity enhanced TCRs
- ADP-600 was subjected to an extensive preclinical testing package, where it demonstrated high potency toward PRAME-positive tumor cells while maintaining stringent specificity against the target antigen



Leveraging all aspects of PRAME opportunity and Adaptimmune strengths



Engineered
TCR



Next-gen enhancements



Integrated manufacturing
capabilities



Solid tumor
target

ADP-520 targeting CD70: TRuC technology to address broad range of cancers

- ✓ Expression in normal cells limited to a subset of activated T-cells, B-cells and dendritic cells
- ✓ **Path to first-in-class autologous CD70 cell therapy with membrane bound IL-15 to enhance persistence**
- ✓ Clinically validated target: POC demonstrated in AML with α CD70 mAb in AML (argenx)



Versatile target expressed in:


- **hematological malignancies: acute myeloid leukemia (AML), lymphoma**
- **solid tumors: renal cell carcinoma (RCC)**



Cell therapy manufacturing and supply chain




Effective delivery of Tecelra from in-house manufacturing



Patient Cell Journey: Typically, 4-6 weeks from collection to product release*

Adaptimmune manufacturing by the numbers





The Time to Redefine Cancer Therapies is Now

*Arming cells. Against cancer. For good.
For Patients. For Physicians. For the Future.*

Adaptimmune by the numbers

We are proud of our people and their success



Adaptimmune leadership

Committed to the promise of cell therapy; Relevant big pharma and small biotech expertise



Adrian (Ad) Rawcliffe
Chief Executive Officer



William (Bill) Bertrand
Chief Operating Officer



Joanna (Jo) Brewer, Ph.D.
Chief Scientific Officer



Karen Chagin, M.D.
Senior Vice President
Early-Stage Development



John Lunger
Chief Patient Supply
Officer



Cintia Piccina
Chief Commercial Officer



Elliot Norry, M.D.
Chief Medical Officer



Kerry Sharp
Senior Vice President
General Counsel



Helen Tayton-Martin, Ph.D., M.B.A.
Chief Business & Strategy
Officer



Dennis Williams, Pharm.D.
Senior Vice President
Late-Stage Development



Gavin Wood
Chief Financial Officer



Adaptimmune: redefining the treatment of solid tumor cancers with cell therapy

High Value Sarcoma Franchise



- US franchise peak year sales up to **\$400m**
- **2024** Tecelra launched
- **2026** lete-cel planned launch



Robust Clinical Pipeline

- **Significant opportunity** in solid tumors
- **>100,000** patients per year

Integrated Cell Therapy Company



- Capabilities to **deliver cell therapies**
- Up to **70% gross margin** at peak



Arming cells. Against cancer. For good.